Victory Capital Management Inc. Raises Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Victory Capital Management Inc. increased its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 65.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 54,034 shares of the biopharmaceutical company’s stock after purchasing an additional 21,355 shares during the period. Victory Capital Management Inc.’s holdings in TG Therapeutics were worth $1,626,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the business. State Street Corp raised its holdings in shares of TG Therapeutics by 35.8% during the third quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock worth $212,712,000 after purchasing an additional 2,398,015 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in TG Therapeutics by 7.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,269,513 shares of the biopharmaceutical company’s stock valued at $38,212,000 after buying an additional 84,904 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in TG Therapeutics by 10.5% in the fourth quarter. Bank of New York Mellon Corp now owns 923,488 shares of the biopharmaceutical company’s stock valued at $27,797,000 after buying an additional 87,679 shares in the last quarter. Principal Financial Group Inc. increased its holdings in TG Therapeutics by 7.5% in the fourth quarter. Principal Financial Group Inc. now owns 830,184 shares of the biopharmaceutical company’s stock valued at $24,989,000 after buying an additional 57,996 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in TG Therapeutics by 60.0% in the third quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company’s stock valued at $16,859,000 after buying an additional 270,286 shares in the last quarter. Hedge funds and other institutional investors own 58.58% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. JPMorgan Chase & Co. lifted their price objective on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a report on Monday, November 25th. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 price objective on shares of TG Therapeutics in a report on Tuesday, March 4th. Finally, StockNews.com raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $40.67.

Insider Buying and Selling

In related news, CFO Sean A. Power sold 10,021 shares of the business’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $28.53, for a total transaction of $285,899.13. Following the transaction, the chief financial officer now directly owns 660,611 shares in the company, valued at approximately $18,847,231.83. The trade was a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 10.50% of the stock is currently owned by company insiders.

TG Therapeutics Stock Down 2.9 %

Shares of NASDAQ TGTX opened at $39.88 on Wednesday. The company’s 50-day simple moving average is $32.35 and its 200-day simple moving average is $29.32. TG Therapeutics, Inc. has a 52-week low of $12.93 and a 52-week high of $41.85. The firm has a market cap of $6.26 billion, a price-to-earnings ratio of -398.76 and a beta of 2.30. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business had revenue of $108.19 million for the quarter, compared to analyst estimates of $100.67 million. Equities analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.